Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow NovAccess Global Inc.

Get SEC filing alerts via email and in your feed for NovAccess Global Inc.

XSNX

NovAccess Global Inc.

About NovAccess Global Inc.

NovAccess Global Inc. is a biopharmaceutical company developing immunotherapies for brain cancer, focusing on dendritic cell-based vaccines targeting glioblastoma. It advances novel treatments through preclinical and clinical trials, seeking FDA approval and orphan drug designation. The company plans to license successful products to larger firms, aiming to address unmet medical needs with personalized, immune-based cancer therapies.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from NovAccess Global Inc.

1
1
NovAccess Global Inc. NovAccess Global Inc. Reports No Revenue and $2.66 Million Net Loss for Fiscal Year Ending September 30, 2024

Via official filing (AI summary) | 5 months ago | 0 comments

2
1
NovAccess Global Inc. NovAccess Global Inc. Reports No Revenue, Net Loss in Latest Quarter, Seeks Additional Funding

Via official filing (AI summary) | over 1 year ago | 0 comments